Industry research
Orthopedic devices
Scope
Europe
Companies
116
Key takeaways
What is the scope of this industry report?
The US specialist care market comprises companies that provide specialist health and support services for individuals with intellectual and developmental disabilities (I/DD), autism spectrum disorder (ASD), serious mental illness (SMI), substance use disorder (SUD), acquired brain injury (ABI) and other complex, often lifelong care needs. These providers deliver residential and inpatient treatment, behavioral health, rehabilitation, applied behavior analysis (ABA) therapy, personal care, habilitation, supported living, case management and other specialist services across healthcare facilities, homes, schools and community settings. Revenue is predominantly derived from Medicaid fee-for-service reimbursement, supplemented by commercial insurance and private-pay funding in selected care settings.
We segmented the US market by care-delivery model into:
Facility-based,
Home- and community-based,
Mixed.
What does the orthopedic devices landscape look like in the US?
The US specialist care landscape remains highly fragmented across all segments, with a limited number of scaled multi-state platforms operating alongside a broad base of regional, local and condition-focused providers. Facility-based providers primarily compete on clinical specialization, treatment capacity and geographic reach, while home- and community-based providers differentiate through workforce availability, referral relationships and local service density. By contrast, mixed-model providers differentiate through a continuum-of-care approach that spans multiple settings, diversifying revenue across per-diem, hourly and unit-based reimbursement streams and reducing reliance on occupancy within any single care setting. Consolidation continues across the industry as strategic and sponsor-backed platforms pursue acquisitions to expand geographic coverage, strengthen clinical capabilities and broaden service offerings.
What does the orthopedic devices market landscape look like in US?
Sponsor-led interest remains high, with ~56% of identified assets being sponsor-backed (July 2026).
Herein, investors are primarily attracted to:
The rising prevalence of autism and other I/DD conditions that expands the long-term beneficiary base for specialist care services,
Wider technology adoption that improves documentation, operational efficiency and access to care,
The shift toward value-based, integrated behavioral health models that create new reimbursement opportunities for coordinated, outcomes-focused providers.
Key deterring factors for investment include:
Persistent workforce shortages that increase labor costs and constrain service capacity,
Variation in Medicaid HCBS assessment and authorization requirements that increase administrative complexity and limit multi-state expansion,
Tightening payer prior authorization and medical-necessity requirements that reduce authorized service volumes and increase reimbursement pressure, particularly in autism therapy.
What are the key ESG considerations in the US orthopedic devices industry?
ESG topics primarily relate to social and governance issues. Social concerns center on safeguarding vulnerable populations, maintaining quality of care, preventing abuse and neglect, as well as supporting the recruitment, training and retention of a labor-intensive direct-care workforce. To address these risks, identified providers invest in workforce development, clinical quality systems, accreditation, safeguarding protocols and caregiver retention initiatives. Governance concerns primarily relate to reimbursement compliance, documentation integrity, regulatory oversight and protection of sensitive patient information across increasingly digital care environments. Accordingly, providers invest in enterprise compliance frameworks, cybersecurity programs, access controls and privacy governance to support reimbursement integrity, regulatory compliance and secure care delivery.
Company benchmarking
Market growth
Technavio (November 2024) estimates that the global autism spectrum disorder market generated ~$7.8bn in revenue in 2024 and expects it to reach ~$11.2bn by 2029 (+7.6% CAGR 2024-2029)
The US home healthcare market is projected to grow from ~$297.5bn in 2020 to ~$510.0bn in 2027 (+8.0% CAGR 2020-2027; Forbes, November 2024)
Positive drivers
Rising prevalence of autism and other I/DD is expected to expand the eligible beneficiary base for specialist care services. To illustrate, the CDC reported that US autism prevalence among 8-year-olds increased from 1 in 36 in 2020 to 1 in 31 in 2022, supporting long-term demand for facility-based, home- and community-based and mixed specialist care models (RISP, January 2026; CDC, May 2025)
Wider adoption of technology will improve efficiency and access across the industry. AI-enabled documentation, electronic health records, automated scheduling and data-driven care tools continue to reduce administrative workloads and improve care coordination. For instance, a large US rollout of ambient AI scribes reduced documentation time by an average of ~1 hour per physician per day (Behavioral Health Business, November 2025; Medicaid, 2025; AMA, March 2024)
The shift toward value-based, integrated behavioral health care will create new reimbursement pathways that favor coordinated, outcomes-focused providers. Supporting this transition, CMS (Centers for Medicare & Medicaid Services) plans to run the Innovation in Behavioral Health Model from 2025 to 2032, aligning Medicaid and Medicare payments around whole-person care and expanding participation through a second cohort of states (CMS, June 2026)
Negative drivers
Persistent workforce shortages are expected to increase labor costs and constrain specialist care capacity. To illustrate, ~40% of the US population resides in mental health professional shortage areas, with the Health Resources and Services Administration further projecting significant shortages across behavioral health occupations through 2038 (HRSA Health Workforce, December 2025)
Variation in Medicaid HCBS assessment and authorization requirements across states is expected to increase administrative complexity and hinder multi-state expansion for specialist care providers. To illustrate, the ‘2024 Ensuring Access to Medicaid Services Rule’ adds further complexity by introducing new federal requirements, including standardized incident reporting, grievance procedures, periodic needs reassessments and phased quality reporting requirements through 2030 (Public Consulting Group, July 2025)
Tightening payer prior authorization and medical-necessity requirements are expected to reduce authorized service volumes and increase reimbursement pressure for specialist care providers, particularly in autism therapy. Industry stakeholders expect lower authorized applied behavior analysis (ABA) service hours, stricter medical-necessity criteria and increased payer audits, which may delay reimbursement or constrain revenue growth (Behavioral Health Business, January 2026)
Fill out the form to request your copy of the Orthopedic devices industry report
With the full report, you’ll gain access to:
Detailed assessments of the market outlook
Insights from c-suite industry executives
A clear overview of all active investors in the industry
An in-depth look into 116 private companies, incl. financials, ownership details and more.
A view on all 341 deals in the industry
ESG assessments with highlighted ESG outperformers
Discover hundreds of niche industry reports on Gain
Deep dive into additional industries to understand their market outlook, positive and negative drivers, and more!
